EMA (European Medicines Agency) and HMA (Heads of Medicines Agencies) are two distinct organizations that play vital roles in the regulation of medicinal products, but their functions and scopes differ.

Arvinas has initiated a deal with Novartis that encompasses a worldwide licensing pact to advance and market their PROTAC® technology-based AR degrader ARV-766, aimed at prostate cancer therapies.

Information on ongoing clinical drug trials worldwide can be accessed through the several channels.

Alpine Immune Sciences Reports New Clinical Data for Povetacicept in IgA Nephropathy.

Several approaches can be employed to swiftly follow the latest global developments in new drug research and development.

Macomics Discloses Pioneering Anti-Pan-LILRB Antibody Initiative, Showcasing Encouraging Preclinical Results at 2024 AACR Event.

The process of bringing a new drug from research and development to market is a long and complex journey.

Tallac Therapeutics Unveils Novel Preclinical Findings for TAC-001 Paired with Oncology Vaccines at AACR's 2024 Yearly Convention.

April 16th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

At the AACR 2024, Crescendo Biologics showcased early-stage findings for its primary investigational drug, CB307, while also revealing CB699, their inaugural dual-functioning immune cell attractor.

The study reveals a structure-guided strategy for biased drug optimization and has led to the development of two biased agonist drug candidates targeting the APLNR receptor.

4.8-4.14 Global Drug R&D Progress & Pharmaceutical Transaction Trends.